CR20120087A - Anticuerpos del antígeno carcinoembrionario (cea) - Google Patents

Anticuerpos del antígeno carcinoembrionario (cea)

Info

Publication number
CR20120087A
CR20120087A CR20120087A CR20120087A CR20120087A CR 20120087 A CR20120087 A CR 20120087A CR 20120087 A CR20120087 A CR 20120087A CR 20120087 A CR20120087 A CR 20120087A CR 20120087 A CR20120087 A CR 20120087A
Authority
CR
Costa Rica
Prior art keywords
abms
relates
present
antibodies
cea
Prior art date
Application number
CR20120087A
Other languages
English (en)
Spanish (es)
Inventor
Thomas U Hofer
Ralf Hosse
Ekkehard Moessner
Pablo Umana
Original Assignee
Roche Glycart Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42985489&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20120087(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag
Publication of CR20120087A publication Critical patent/CR20120087A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CR20120087A 2009-08-31 2012-02-20 Anticuerpos del antígeno carcinoembrionario (cea) CR20120087A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23850509P 2009-08-31 2009-08-31

Publications (1)

Publication Number Publication Date
CR20120087A true CR20120087A (es) 2012-03-22

Family

ID=42985489

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20120087A CR20120087A (es) 2009-08-31 2012-02-20 Anticuerpos del antígeno carcinoembrionario (cea)

Country Status (22)

Country Link
US (2) US9068008B2 (https=)
EP (1) EP2473532B1 (https=)
JP (1) JP5744872B2 (https=)
KR (1) KR101528013B1 (https=)
CN (1) CN102741293B (https=)
AR (1) AR078111A1 (https=)
AU (1) AU2010288469A1 (https=)
BR (1) BR112012003983A2 (https=)
CA (1) CA2770174A1 (https=)
CL (1) CL2012000551A1 (https=)
CO (1) CO6491105A2 (https=)
CR (1) CR20120087A (https=)
EC (1) ECSP12011698A (https=)
IL (1) IL218038A0 (https=)
MA (1) MA33536B1 (https=)
MX (1) MX339608B (https=)
PE (1) PE20121552A1 (https=)
RU (1) RU2570554C2 (https=)
SG (1) SG178567A1 (https=)
TW (1) TW201121994A (https=)
WO (1) WO2011023787A1 (https=)
ZA (1) ZA201200954B (https=)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5992710A (ja) * 1982-11-16 1984-05-29 関西電力株式会社 直接水冷線路の立坑部の布設方法
NZ571596A (en) 2001-08-03 2010-11-26 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
KR20130118941A (ko) 2011-02-10 2013-10-30 로슈 글리카트 아게 면역치료법
SG192673A1 (en) 2011-02-10 2013-09-30 Roche Glycart Ag Mutant interleukin-2 polypeptides
PE20141017A1 (es) * 2011-03-02 2014-08-25 Roche Glycart Ag Anticuerpos del cea
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
WO2013026839A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
EP2748202B1 (en) 2011-08-23 2018-07-04 Roche Glycart AG Bispecific antigen binding molecules
NO2748201T3 (https=) 2011-08-23 2018-05-12
WO2013054320A1 (en) 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
GB201213858D0 (en) 2012-08-03 2012-09-19 Mab Design Ltd Method
MY175687A (en) 2012-08-07 2020-07-06 Roche Glycart Ag Composition comprising two antibodies engineered to have reduced and increased effector function
RU2015117393A (ru) 2012-10-08 2016-12-10 Роше Гликарт Аг Лишенные fc антитела, содержащие два Fab-фрагмента, и способы их применения
EP2961773B1 (en) 2013-02-26 2019-03-20 Roche Glycart AG Bispecific t cell activating antigen binding molecules
LT2961771T (lt) 2013-02-26 2020-03-10 Roche Glycart Ag Bispecifinės t ląstelę aktyvinančios antigeną surišančios molekulės, specifinės cd3 ir cea antigenams
EP2961770A1 (en) * 2013-02-26 2016-01-06 Roche Glycart AG Bispecific t cell activating antigen binding molecules
US11427647B2 (en) 2014-04-27 2022-08-30 Famewave Ltd. Polynucleotides encoding humanized antibodies against CEACAM1
US10550196B2 (en) 2014-04-27 2020-02-04 Famewave Ltd. Humanized antibodies against CEACAM1
EP3177643B1 (en) 2014-08-04 2019-05-08 F.Hoffmann-La Roche Ag Bispecific t cell activating antigen binding molecules
EP4141032B1 (en) 2014-11-20 2024-05-29 F. Hoffmann-La Roche AG Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists
PT3221356T (pt) 2014-11-20 2020-10-29 Hoffmann La Roche Moléculas de ligação ao antigénio biespecíficas ativadoras das células t contra folr1 e cd3
DK3221357T3 (da) 2014-11-20 2020-08-10 Hoffmann La Roche Fælles letkæder og fremgangsmåder til anvendelse
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
PE20180484A1 (es) 2015-10-02 2018-03-07 Hoffmann La Roche Moleculas biespecificas de union a antigeno activadoras de celulas t
IL313608A (en) 2015-12-09 2024-08-01 Hoffmann La Roche Antibody against CD20 type II to reduce the formation of antibodies against drugs
KR20180097615A (ko) 2016-01-08 2018-08-31 에프. 호프만-라 로슈 아게 Pd-1 축 결합 길항물질 및 항-cea/항-cd3 이중특이성 항체를 사용하는 cea-양성 암의 치료 방법
JP7015244B2 (ja) 2016-03-22 2022-02-02 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト プロテアーゼ活性化ｔ細胞二重特異性分子
CN107663240B (zh) 2016-07-29 2021-01-12 中国人民解放军第四军医大学 高度糖基化cea特异性结合的单链抗体及其在检测和治疗上的应用
US10882918B2 (en) 2016-09-30 2021-01-05 Hoffmann-La Roche Inc. Bispecific T cell activating antigen binding molecules
IL325995A (en) 2018-02-08 2026-03-01 Genentech Inc Bispecific antigen binding molecules and methods of use
TWI890481B (zh) 2018-02-09 2025-07-11 日商小野藥品工業股份有限公司 雙特異性抗體
CN113906053B (zh) * 2019-06-26 2022-10-25 江苏恒瑞医药股份有限公司 抗cea抗体及其应用
KR20220025848A (ko) 2019-06-26 2022-03-03 에프. 호프만-라 로슈 아게 Cea 및 4-1bbl에 결합하는 항체의 융합
CN110713539B (zh) * 2019-09-23 2021-04-16 华道(上海)生物医药有限公司 一种抗癌胚抗原的抗体及其制备方法和用途
CN110862456B (zh) * 2019-09-23 2021-04-09 华道(上海)生物医药有限公司 一种抗癌胚抗原的抗体及其制备方法和用途
WO2021255155A1 (en) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Antibodies binding to cd3 and cd19
IL300500A (en) 2020-08-20 2023-04-01 A2 Biotherapeutics Inc Preparations and methods for the treatment of mesothelin positive cancer
CA3188867A1 (en) 2020-08-20 2022-02-24 Xueyin Wang Compositions and methods for treating ceacam positive cancers
CA3213632A1 (en) 2021-04-30 2022-11-03 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
JP2024519078A (ja) * 2021-05-21 2024-05-08 ベイジーン スウィッツァーランド ゲーエムベーハー 抗ｃｅａ抗体及びその使用方法
AU2023212292A1 (en) * 2022-01-27 2024-09-12 Janssen Biotech, Inc. Enhanced protein compositions
KR20250024741A (ko) 2022-03-23 2025-02-19 시나픽스 비.브이. 암배아성 항원을 발현하는 종양을 표적화하기 위한 항체-컨쥬게이트
EP4724490A2 (en) 2023-06-12 2026-04-15 Amgen Inc. Lymphotoxin beta receptor agonist binding proteins
WO2025257185A1 (en) * 2024-06-11 2025-12-18 Abcely Humanized anti-human-carcinoembryonic antigen antibody

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
US5872215A (en) 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
AU672951B2 (en) * 1992-05-07 1996-10-24 Ge Healthcare As Complexing agents and targeting immunoreagents
GB9317423D0 (en) * 1993-08-21 1993-10-06 Imp Cancer Res Tech Monoclonal antibodies
GB9324807D0 (en) 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6417337B1 (en) 1996-10-31 2002-07-09 The Dow Chemical Company High affinity humanized anti-CEA monoclonal antibodies
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
AU8822601A (en) 2000-07-31 2002-02-13 Biolex Inc Expression of biologically active polypeptides in duckweed
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6815175B2 (en) * 2001-03-16 2004-11-09 Cornell Research Foundation, Inc. Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
NZ571596A (en) 2001-08-03 2010-11-26 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
CA2471551C (en) 2001-12-27 2014-09-30 Glycofi, Inc. Methods to engineer mammalian-type carbohydrate structures
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
US20070148171A1 (en) * 2002-09-27 2007-06-28 Xencor, Inc. Optimized anti-CD30 antibodies
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
CN1665934B (zh) 2002-03-19 2010-05-26 国际植物研究所 GNTIII(UDP-N乙酰葡萄糖胺:β-D-甘露糖苷β(1,4)-N-乙酰葡萄糖胺基-转移酶III)在植物中的表达
CA2481658A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to fcy receptor iiia
ATE503829T1 (de) 2002-04-09 2011-04-15 Kyowa Hakko Kirin Co Ltd Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
CA2481925A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for patients having human fc.gamma.riiia
BR0309145A (pt) 2002-04-09 2005-02-01 Kyowa Hakko Kogyo Kk Células das quais o genoma é modificado
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING ANTIBODY COMPOSITION
US7232888B2 (en) 2002-07-01 2007-06-19 Massachusetts Institute Of Technology Antibodies against tumor surface antigens
JP5138867B2 (ja) * 2002-08-01 2013-02-06 イミューノメディクス、インコーポレイテッド α−フェトタンパク質Ｉｍｍｕ３１抗体および融合タンパク質ならびにその使用方法
EP1539966B1 (en) 2002-09-12 2010-06-30 Greenovation Biotech GmbH Protein production method
WO2004057002A2 (en) 2002-12-20 2004-07-08 Greenovation Biotech Gmbh Production of heterologous glycosylated proteins in bryophyte cells
CA2512729C (en) 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
EP2248892B1 (en) 2003-01-22 2015-04-22 Roche Glycart AG Fusion constructs and use of same to produce antibodies with increased FC receptor binding affinity and effector function
US20090005257A1 (en) * 2003-05-14 2009-01-01 Jespers Laurent S Process for Recovering Polypeptides that Unfold Reversibly from a Polypeptide Repertoire
PE20141017A1 (es) * 2011-03-02 2014-08-25 Roche Glycart Ag Anticuerpos del cea

Also Published As

Publication number Publication date
CA2770174A1 (en) 2011-03-03
WO2011023787A1 (en) 2011-03-03
ECSP12011698A (es) 2012-03-30
MA33536B1 (fr) 2012-08-01
RU2570554C2 (ru) 2015-12-10
IL218038A0 (en) 2012-04-30
HK1176951A1 (en) 2013-08-09
EP2473532A1 (en) 2012-07-11
US20160075795A1 (en) 2016-03-17
MX339608B (es) 2016-05-31
US20110104148A1 (en) 2011-05-05
RU2012112340A (ru) 2013-10-10
JP2013502913A (ja) 2013-01-31
US9068008B2 (en) 2015-06-30
CN102741293A (zh) 2012-10-17
CO6491105A2 (es) 2012-07-31
BR112012003983A2 (pt) 2021-09-14
AU2010288469A1 (en) 2012-03-01
MX2012002461A (es) 2012-03-14
SG178567A1 (en) 2012-04-27
AR078111A1 (es) 2011-10-12
CL2012000551A1 (es) 2012-10-12
KR101528013B1 (ko) 2015-06-16
TW201121994A (en) 2011-07-01
EP2473532B1 (en) 2017-06-21
JP5744872B2 (ja) 2015-07-08
PE20121552A1 (es) 2012-11-26
KR20120060874A (ko) 2012-06-12
ZA201200954B (en) 2014-07-30
CN102741293B (zh) 2015-04-01

Similar Documents

Publication Publication Date Title
CR20120087A (es) Anticuerpos del antígeno carcinoembrionario (cea)
ECSP21023271A (es) Anticuerpos cd20 con función del efector y afinidad de enlace al receptor fc mejoradas
AR055137A1 (es) Moleculas de union al antigeno modificadas con actividad de senalizacion celular alterada
AR052285A1 (es) Moleculas de union al antigeno que fijan egfr, vectores que las codifican y usos de las mismas
AR062223A1 (es) Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
CL2021001986A1 (es) Anticuerpos y receptores quiméricos de antígenos específicos para receptor 1 huérfano tipo receptor tirosina-cinasa (ror1).
AR052714A1 (es) Moleculas fijadoras de antigeno dirigidas a mcsp y con aumento de afinidad de fijacion a receptor fc y de funcion efectora
UA114108C2 (uk) Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання
EA030777B9 (ru) Анти-альфа-синуклеинсвязывающие молекулы
MX2010009190A (es) Anticuerpos anti-c5ar humanizados.
BR112012018914A2 (pt) "anticorpo humanizado, proteína de ligação de antígeno, molécula de ácido nucleico, vetor de expressão, célula hospedeira recombinante, proteína de ligação de anticorpo ou de antígeno, métodos para a produção de uma proteína de ligação de antígeno e para tratar um sujeito afetado por uma doença autoimune ou inflamatória, e, composição farmacêutica."
CR8389A (es) Anticuerpos cd20 con funcion del efector y afinidad de enlace al receptor fc mejoradas